Trials / Completed
CompletedNCT02988115
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 345 (actual)
- Sponsor
- Esperion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bempedoic acid | bempedoic acid 180 mg tablet |
| OTHER | placebo | Matching placebo tablet |
Timeline
- Start date
- 2016-11-16
- Primary completion
- 2018-03-16
- Completion
- 2018-03-16
- First posted
- 2016-12-09
- Last updated
- 2020-04-03
- Results posted
- 2020-04-03
Locations
67 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02988115. Inclusion in this directory is not an endorsement.